Ascendis Challenges BioMarin, But Market Response Seems Excessive
Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...
Buy Rating on Ascendis Pharma as TransCon CNP Triumphs in Trials, with Raised Target Price to $207
In a report released yesterday, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
Business Insider6d
Optimistic Buy Rating for Ascendis Pharma on TransCon CNP’s Market Potential and Regulatory Prospects
The analyst highlights the significance of TransCon CNP’s success in treating achondroplasia (ACH), reflected in the increased price target to $289. This optimism is rooted in the potential for ...
Nasdaq6d
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Shares of Ascendis Pharma ASND rose 17% on Monday after it reported top-line results from the pivotal ApproaCH study that evaluated investigational once-weekly administered TransCon CNP in ...
FierceBiotech6d
Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
BioMarin serves that need with its CNP analog Voxzogo—the centerpiece of its growth strategy—but that drug needs to be ...
BioPharma Dive6d
Ascendis trial data piles pressure on BioMarin
Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.